Audited Financial Results for the year ended 31 st December 2021
Dear Sirs,
We refer to our letter dated 7th February 2022 informing you of our Board Meeting that was scheduled today. The meeting of Board of Directors commenced at 2.30 p.m. and concluded at 6.15 p.m. The Board approved audited financial results for the quarter and year ended 31st December 2021.
We enclose a copy of the auditor's report and audited financial results of the Company for the quarter and year ended 31st December 2021 along with statement of assets and liabilities as on that date and statement of cashflows for the year ended 31st December 2021 along with press release as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for your information.
Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare that the Statutory Auditors of the Company, M/s Price Waterhouse & Co. Chartered Accountants LLP have issued the Audit Report with unmodified opinion for the financial year ended 31st December 2021.
Please take the above information on record.
Thanking you,
Yours faithfully
For Sanofi India Limited
Radhika Shah
Company Secretary &Compliance Officer
Membership No.: 19308
Sanofi India Limited, Sanofi House, CTS No. 117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai 400 072 - India - Tel.: +91(22) 2803 2000 - Fax: +91(22) 2803 2939
Corporate Identity Number: L24239MH1956PLC009794
Website: www.sanofiindialtd.com I www.sanofi.in
Email: igrc.sil@sanofi.com
SANOFI INDIA LIMITED
Registered Office : Sanofi House,C.T.S No - 117-8, L & T Business Park, Saki Vihar Road, Powai, Mumbai 400 072.
Corporate Identity Number: L24239MH1956PLC009794
Tel no: (91-22) 28032000
Fax No: (91-22) 28032846
Website: www.sanofiindialtd.com
Email: igrc.sil@sanofi.com
STATEMENT OF AUDITED FINANCIAL RESULTS FOR YEAR ENDED DECEMBER 31, 2021
Quarter
Quarter
Quarter
Year
Particulars
ended
ended
ended
ended
31.12.2021
30.09.2021
31.12.2020
31.12.2021
(Audited)
(Audited)
Refer Note 7
(Unaudited)
Refer Note 7
(Audited)
1. Revenue from Operations
6,879
7,545
7,203
29,566
2. Other Income
163
147
162
744
3. Total Income (1+2)
7,042
7,692
7,365
30,310
4. Expenses
(a) Cost of Materials Consumed
1,288
1,456
1,483
5,551
(b) Purchases of stock in trade
1,670
1,996
1,609
7,086
(c) Olanges in Inventories of finished goods, work-in-progress and stock-in-trade
126
(130)
68
431
(d) Employee benefits expense
1,082
1,074
1,072
4,339
(e) Finance costs
4
5
4
18
(f) Depreciation and amortisation expense
109
143
204
667
(g) Other expenses
1,441
1,161
1,301
4,534
Total Expenses
5,720
5,705
5,741
22,626
5. Profit before exceptional item and tax (3-4)
1,322
1,987
1,624
7,684
6. Exceptional item (Refer notes 4 & 5)
-
4,892
78
4,892
7. Profit before tax (5+6)
1,322
6,879
1,702
12,576
8. Tax expense
Current Tax
430
1,714
467
3,360
Deferred Tax
(12)
(133)
5
(228)
9. Profit for the year/period (7-8)
904
5,298
1,230
9,444
10. Other comprehensive income (00) (Net of Tax)
(33)
-
(51)
(33)
11. Total comprehensive income for the year/period (9+10)
871
5,298
1,179
9,411
12. Paid-up equity share capital (Face Value of� 10 per share)
230
230
230
230
13. Other equity
-
-
-
22,026
14. Basic and diluted earnings per share (not annualised)
39.25
230.04
53.41
410.06
in Million
Year
ended
31.12.2020
(Audited)
29,019
898
29,917
5,914
6,047
575
4,608
18
822
4,744
22,728
7,189
(417)
6,772
2,110
(114)
4,776
(88)
4,688
230
20,960
207.38
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Sanofi India Ltd. published this content on 24 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 February 2022 11:12:31 UTC.
Sanofi India Limited is an India-based company, which is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. The Company produces pharmaceutical formulations, dosage forms and offer a range of medicines across various therapeutic areas. Its product portfolio is focused on five therapeutic areas: diabetes, epilepsy, cardiology, allergy and pain care. In the diabetes area, the Company has an insulin portfolio under the brand name of Lantus, which helps in controlling high blood sugar in adults and children with diabetes mellitus. It also provides Toustar pen, along with dedicated Toujeo cartridges, addressing the need for a reusable delivery device. Combiflam, its product, helps to reduce pain and inflammation in conditions like headache, muscle and joint pain, and also reduces fever. Its brands also include Cardace, Allegra, Avil and Frisium. The Company has its own manufacturing facility in Goa. It has around 12 contract manufacturing organizations.